Dual role of tumour-infiltrating T helper 17 cells in human colorectal cancer

Gut

Volumn 66, Issue 4, 2017, Pages 692-704

  Amicarella, F ^a   Muraro, M G ^a   Hirt, C ^a   Cremonesi, E ^a   Padovan, E ^a   Mele, V ^a   Governa, V ^a   Han, J ^a,b   Huber, X ^a,c   Droeser, R A ^c   Zuber, M ^d   Adamina, M ^e   Bolli, M ^f   Rosso, R ^g   Lugli, A ^h   Zlobec, I ^h   Terracciano, L ^a   Tornillo, L ^a   Zajac, P ^a   Eppenberger Castori, S ^a   Trapani, F ^a   Oertli, D ^c   Iezzi, Giandomenica ^a   more..

^a UNIVERSITY OF BASEL   (Switzerland)

^b TONGJI UNIVERSITY   (China)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d KANTONSSPITAL   (Switzerland)

^e CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^f St Claraspital AG   (Switzerland)

^g Ospedale Civico Lugano   (Switzerland)

^h UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR6; INTERLEUKIN 17; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; RANTES; CCL20 PROTEIN, HUMAN; CCL5 PROTEIN, HUMAN; CXCL10 PROTEIN, HUMAN; CXCL9 CHEMOKINE; CXCL9 PROTEIN, HUMAN; FC RECEPTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; PEROXIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST EPITHELIUM CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CLINICAL FEATURE; CLINICAL OUTCOME; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOKINE RELEASE; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MAJOR CLINICAL STUDY; MOUSE; NEUTROPHIL; NONHUMAN; PHENOTYPE; STROMA CELL; TH17 CELL; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE; ADULT; AGED; CHEMISTRY; COLORECTAL TUMOR; CYTOTOXIC T LYMPHOCYTE; ENZYMOLOGY; FEMALE; GENETICS; HT-29 CELL LINE; IMMUNOLOGY; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SECRETION (PROCESS); SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINE CCL20; CHEMOKINE CCL5; CHEMOKINE CXCL10; CHEMOKINE CXCL9; COLORECTAL NEOPLASMS; FEMALE; HT29 CELLS; HUMANS; INTERLEUKIN-17; INTERLEUKIN-8; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEUTROPHILS; PEROXIDASE; PHENOTYPE; PROGNOSIS; RECEPTORS, IGG; SURVIVAL RATE; T-LYMPHOCYTES, CYTOTOXIC; TH17 CELLS;

EID: 84954271232     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-310016     Document Type: Article

References (50)

1. Fridman WH, Pagès F, Sautès-Fridman C, et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012;12:298-306.
2. Frey DM, Droeser RA, Viehl CT, et al. High frequency of tumor-infiltrating FOXP3+ regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer 2010;126:2635-43.
3. Salama P, Phillips M, Grieu F, et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009;27:186-92.
4. Droeser RA, Hirt C, Eppenberger-Castori S, et al. High myeloperoxidase positive cell infiltration in colorectal cancer is an independent favorable prognostic factor. PLoS ONE 2013;8:e64814.
5. Hirt C, Eppenberger-Castori S, Sconocchia G, et al. Colorectal carcinoma infiltration by myeloperoxidase-expressing neutrophil granulocytes is associated with favorable prognosis. Oncoimmunology 2013;2:e25990.
6. Sconocchia G, Zlobec I, Lugli A, et al. Tumor infiltration by FcgammaRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma. Int J Cancer 2011;128:2663-72.
7. Liu J, Duan Y, Cheng X, et al. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun 2011;407:348-54.
8. Tosolini M, Kirilovsky A, Mlecnik B, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011;71:1263-71.
9. Weaver CT, Hatton RD, Mangan PR, et al. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007;25:821-52.
10. Korn T, Bettelli E, Oukka M, et al. IL-17 and Th17 cells. Annu Rev Immunol 2009;27:485-517.
11. Beriou G, Costantino CM, Ashley CW, et al. IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood 2009;113:4240-9.
12. Voo KS, Wang YH, Santori FR, et al. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci U S A 2009;106:4793-8.
13. Koenen HJ, Smeets RL, Vink PM, et al. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008;112:2340-52.
14. Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 2010;10:479-89.
15. Spits H, Artis D, Colonna M, et al. Innate lymphoid cells - a proposal for uniform nomenclature. Nat Rev Immunol 2013;13:145-9.
16. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 2007;13:139-45.
17. Chae WJ, Gibson TF, Zelterman D, et al. Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis. Proc Natl Acad Sci USA 2010;107:5540-4.
18. Chung AS, Wu X, Zhuang G, et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med 2013;19:1114-23.
19. Grivennikov SI, Wang K, Mucida D, et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012;491:254-8.
20. Numasaki M, Fukushi J, Ono M, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003;101:2620-7.
21. Wang K, Kim MK, Di Caro G, et al. Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. Immunity 2014;41:1052-63.
22. Wu S, Rhee KJ, Albesiano E, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009;15:1016-22.
23. Garber K. Anti-IL-17 mAbs herald new options in psoriasis. Nat Biotechnol 2012;30:475-7.
24. Niederreiter L, Adolph TE, Kaser A. Anti-IL-12/23 in Crohn's disease: bench and bedside. Curr Drug Targets 2013;14:1379-84.
25. Tse MT. IL-17 antibodies gain momentum. Nat Rev Drug Discov 2013;12:815-16.
26. Wang K, Grivennikov SI, Karin M. Implications of anti-cytokine therapy in colorectal cancer and autoimmune diseases. Ann Rheum Dis 2013;72(Suppl 2):ii100-3.
27. Middleton GW, Annels NE, Pandha HS. Are we ready to start studies of Th17 cell manipulation as a therapy for cancer? Cancer Immunol Immunother 2012;61:1-7.
28. Zlobec I, Karamitopoulou E, Terracciano L, et al. TIA-1 cytotoxic granule-associated RNA binding protein improves the prognostic performance of CD8 in mismatch repair-proficient colorectal cancer. PLoS One 2010;5:e14282.
29. Zlobec I, Steele R, Terracciano L, et al. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol 2007;60:1112-16.
30. Acosta-Rodriguez EV, Rivino L, Geginat J, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007;8:639-46.
31. Hirt C, Papadimitropoulos A, Muraro MG, et al. Bioreactor-engineered cancer tissue-like structures mimic phenotypes, gene expression profiles and drug resistance patterns observed "in vivo". Biomaterials 2015;62:138-46.
32. Lugli A, Karamitopoulou E, Panayiotides I, et al. CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer. Br J Cancer 2009;101:1382-92.
33. Hot A, Lenief V, Miossec P. Combination of IL-17 and TNFalpha induces a pro-inflammatory, pro-coagulant and pro-thrombotic phenotype in human endothelial cells. Ann Rheum Dis 2012;71:768-76.
34. Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 2010;129:311-21.
35. Musha H, Ohtani H, Mizoi T, et al. Selective infiltration of CCR5(+)CXCR3(+) T lymphocytes in human colorectal carcinoma. Int J Cancer 2005;116:949-56.
36. Braccini A, Wendt D, Jaquiery C, et al. Three-dimensional perfusion culture of human bone marrow cells and generation of osteoinductive grafts. Stem Cells 2005;23:1066-72.
37. Blatner NR, Bonertz A, Beckhove P, et al. In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proc Natl Acad Sci USA 2010;107:6430-5.
38. Kryczek I, Wu K, Zhao E, et al. IL-17+ Regulatory T Cells in the microenvironments of chronic inflammation and cancer. J Immunol 2011;186:4388-95.
39. Su X, Ye J, Hsueh EC, et al. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol 2010;184:1630-41.
40. Yang S, Wang B, Guan C, et al. Foxp3+IL-17+ T cells promote development of cancer-initiating cells in colorectal cancer. J Leukoc Biol 2011;89:85-91.
41. Wu P, Wu D, Ni C, et al. GammadeltaT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity 2014;40:785-800.
42. Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature 2012;486:222-7.
43. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science 2012;336:1268-73.
44. Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009;139:485-98.
45. Ankathatti MM, Deng Y, Mulligan SJ, et al. Th17 and Th17-stimulated CD8(+) T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity. Cancer Immunol Immunother 2011;60:1473-84.
46. Martin-Orozco N, Muranski P, Chung Y, et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009;31:787-98.
47. Murugaiyan G, Saha B. Protumor vs antitumor functions of IL-17. J Immunol 2009;183:4169-75.
48. Punt S, Langenhoff JM, Putter H, et al. The correlations between IL-17 vs. Th17 cells and cancer patient survival: a systematic review. Oncoimmunology 2015;4:e984547.
49. Wilke CM, Kryczek I, Wei S, et al. Th17 cells in cancer: help or hindrance? Carcinogenesis 2011;32:643-9.
50. Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 2010;10:248-56.